We have located links that may give you full text access.
Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer.
Anticancer Research 2017 March
BACKGROUND/AIM: We evaluated whether sub-stratifying intermediate-risk (IR) prostate cancer using the Memorial Sloan Kettering Cancer (MSKCC) or Prostate Cancer Risk Stratification (ProCaRS) model predicts for adverse imaging or pathologic features.
PATIENTS AND METHODS: 56 consecutive IR patients who underwent multi-parametric MRI (mpMRI) and radical prostatectomy (RP) were studied. The different groups were tested for correlation with adverse findings. 2-sample T-tests assuming unequal variance were used.
RESULTS: On mpMRI the MSKCC unfavorable group had higher index lesion suspicion scores (p=0.044), while the ProCaRS model showed a higher maximum tumor diameter (MTD) in the high-risk group (p=0.047). At RP, a higher pathologic MTD (23.3 vs. 17.6 mm, p=0.005) was present in the MSKCC unfavorable group as well as the ProCaRS high vs. low group (26.6 vs. 19.3 mm, p=0.022).
CONCLUSION: Both models demonstrated a correlation with higher MTD for unfavorable IR patients. This is likely a driver of worse clinical outcomes.
PATIENTS AND METHODS: 56 consecutive IR patients who underwent multi-parametric MRI (mpMRI) and radical prostatectomy (RP) were studied. The different groups were tested for correlation with adverse findings. 2-sample T-tests assuming unequal variance were used.
RESULTS: On mpMRI the MSKCC unfavorable group had higher index lesion suspicion scores (p=0.044), while the ProCaRS model showed a higher maximum tumor diameter (MTD) in the high-risk group (p=0.047). At RP, a higher pathologic MTD (23.3 vs. 17.6 mm, p=0.005) was present in the MSKCC unfavorable group as well as the ProCaRS high vs. low group (26.6 vs. 19.3 mm, p=0.022).
CONCLUSION: Both models demonstrated a correlation with higher MTD for unfavorable IR patients. This is likely a driver of worse clinical outcomes.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app